Novabay Pharmaceuticals, Inc.2023财年实现净利润-9.64百万美元，同比增加40.75%

自选股智能写手03-27

12月31日，Novabay Pharmaceuticals, Inc.（NBY.US）公布财报，公告显示公司2023财年净利润为-9.64百万美元，同比增加40.75%；其中营业收入为14.73百万美元，同比增加2.29%，每股基本收益为-3.96美元。从资产负债表来看，Novabay Pharmaceuticals, Inc.（NBY.US）总负债5.72百万美元，其中短期债务1.63百万美元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422165918?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 22:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2422165918","market":"us","top_or_hot":-1,"title":"Novabay Pharmaceuticals, Inc.2023财年实现净利润-9.64百万美元，同比增加40.75%","media":"自选股智能写手","content":"<div>\n<p>12月31日，Novabay Pharmaceuticals, Inc.（NBY.US）公布财报，公告显示公司2023财年净利润为-9.64百万美元，同比增加40.75%；其中营业收入为14.73百万美元，同比增加2.29%，每股基本收益为-3.96美元。从资产负债表来看，Novabay Pharmaceuticals, Inc.（NBY.US）总负债5.72百万美元，其中短期债务1.63百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722103687bc95e8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novabay Pharmaceuticals, Inc.2023财年实现净利润-9.64百万美元，同比增加40.75%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovabay Pharmaceuticals, Inc.2023财年实现净利润-9.64百万美元，同比增加40.75%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 22:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722103687bc95e8&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月31日，Novabay Pharmaceuticals, Inc.（NBY.US）公布财报，公告显示公司2023财年净利润为-9.64百万美元，同比增加40.75%；其中营业收入为14.73百万美元，同比增加2.29%，每股基本收益为-3.96美元。从资产负债表来看，Novabay Pharmaceuticals, Inc.（NBY.US）总负债5.72百万美元，其中短期债务1.63百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722103687bc95e8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBY","symbol_name":"NovaBay Pharmaceuticals Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722103687bc95e8&s=b","article_id":"2422165918","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722103687bc95e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422165918","pubTimestamp":1711548624,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月31日，Novabay Pharmaceuticals, Inc.公布财报，公告显示公司2023财年净利润为-9.64百万美元，同比增加40.75%；其中营业收入为14.73百万美元，同比增加2.29%，每股基本收益为-3.96美元。从资产负债表来看，Novabay Pharmaceuticals, Inc.总负债5.72百万美元，其中短期债务1.63百万美元，资产负债比为1.58，流动比率为1.68。机构评级：截至2023年12月31日，当前有1家机构对Novabay Pharmaceuticals, Inc.目标价做出预测，其中目标均价为3.50美元，其中最低目标价为3.50美元，最高目标价为3.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"NBY":"NovaBay Pharmaceuticals Inc"},"translate_title":"Novabay Pharmaceuticals, Inc. achieved a net profit of-9. 64 million US dollars in fiscal year 2023, an increase of 40.75% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBY":0.9},"content_text":"12月31日，Novabay Pharmaceuticals, Inc.（NBY.US）公布财报，公告显示公司2023财年净利润为-9.64百万美元，同比增加40.75%；其中营业收入为14.73百万美元，同比增加2.29%，每股基本收益为-3.96美元。从资产负债表来看，Novabay Pharmaceuticals, Inc.（NBY.US）总负债5.72百万美元，其中短期债务1.63百万美元，资产负债比为1.58，流动比率为1.68。机构评级：截至2023年12月31日，当前有1家机构对Novabay Pharmaceuticals, Inc.目标价做出预测，其中目标均价为3.50美元，其中最低目标价为3.50美元，最高目标价为3.50美元。公司简介：NovaBay Pharmaceuticals Inc是一家生物制药公司，开发和销售科学创造并经过临床验证的眼部护理和护肤产品。其主导产品Avenova抗微生物眼睑和睫毛液(Avenova Spray)在实验室测试中被证明具有广泛的抗菌性能，因为它可以清除包括眼睑在内的眼部周围皮肤上的微生物和碎片等外来物质。Avenova Spray 可通过在线分销渠道直接向消费者提供，并且还经常由眼科护理专业人员开具处方和配药，用于治疗睑缘炎和干眼症。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422165918"}